Miller RG - Search Results

1

Multifocal motor neuropathy: response to human immune globulin.

Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB, Freimer ML, Miller RG, Griffin JW. Chaudhry V, et al. Among authors: miller rg. Ann Neurol. 1993 Mar;33(3):237-42. doi: 10.1002/ana.410330303. Ann Neurol. 1993. PMID: 8498806

2

Motor conduction studies in Guillain-Barré syndrome: description and prognostic value.

Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, Feasby TE, Quaskey SA. Cornblath DR, et al. Among authors: miller rg. Ann Neurol. 1988 Apr;23(4):354-9. doi: 10.1002/ana.410230407. Ann Neurol. 1988. PMID: 3382170

3

Consistent improvement with eculizumab across muscle groups in myasthenia gravis.

Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Mantegazza R, et al. Ann Clin Transl Neurol. 2020 Aug;7(8):1327-1339. doi: 10.1002/acn3.51121. Epub 2020 Jul 22. Ann Clin Transl Neurol. 2020. PMID: 32700461 Free PMC article. Clinical Trial.

4

Conduction block in clinical practice.

Cornblath DR, Sumner AJ, Daube J, Gilliat RW, Brown WF, Parry GJ, Albers JW, Miller RG, Petajan J. Cornblath DR, et al. Among authors: miller rg. Muscle Nerve. 1991 Sep;14(9):869-71; discussion 867-8. doi: 10.1002/mus.880140913. Muscle Nerve. 1991. PMID: 1922183 No abstract available.

5

'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.

Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. Vissing J, et al. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18. J Neurol. 2020. PMID: 32189108 Free PMC article. Clinical Trial.

6

Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC; Quality Standards Subcommittee of the American Academy of Neurology. Hughes RA, et al. Among authors: miller rg. Neurology. 2003 Sep 23;61(6):736-40. doi: 10.1212/wnl.61.6.736. Neurology. 2003. PMID: 14504313

7

Subacute, reversible motor neuron disease.

Tucker T, Layzer RB, Miller RG, Chad D. Tucker T, et al. Among authors: miller rg. Neurology. 1991 Oct;41(10):1541-4. doi: 10.1212/wnl.41.10.1541. Neurology. 1991. PMID: 1844350

8

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.

Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; REGAIN Study Group. Mantegazza R, et al. Neurology. 2021 Jan 26;96(4):e610-e618. doi: 10.1212/WNL.0000000000011207. Epub 2020 Nov 23. Neurology. 2021. PMID: 33229455 Free PMC article. Clinical Trial.

9

Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.

Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Siddiqi ZA, et al. Muscle Nerve. 2021 Dec;64(6):662-669. doi: 10.1002/mus.27422. Epub 2021 Oct 14. Muscle Nerve. 2021. PMID: 34590717 Clinical Trial.

10

Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of beta-tubulin: clinical association with slowly progressive demyelinating polyneuropathy.

Connolly AM, Pestronk A, Mehta S, Yee WC, Green BJ, Fellin C, Olney RK, Miller RG, Devor WN. Connolly AM, et al. Among authors: miller rg. Neurology. 1997 Jan;48(1):243-8. doi: 10.1212/wnl.48.1.243. Neurology. 1997. PMID: 9008525

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

679 results

Search Page